UK markets closed

Novozymes A/S (NVZMF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
62.15+0.85 (+1.38%)
At close: 03:53PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close61.30
Open61.90
BidN/A x N/A
AskN/A x N/A
Day's range61.35 - 62.65
52-week range54.65 - 82.59
Volume635
Avg. volume1,146
Market cap17.246B
Beta (5Y monthly)0.31
PE ratio (TTM)42.57
EPS (TTM)1.46
Earnings dateN/A
Forward dividend & yield0.82 (1.28%)
Ex-dividend date17 Mar 2022
1y target estN/A
  • Globe Newswire

    Novozymes delivers strong half year results and narrows full-year outlook upwards

    Novozymes delivered solid earnings and double-digit organic sales growth in both the first half and in the second quarter. Despite the volatile market environment, the company narrows its full-year organic sales outlook upwards from 4-8% to now 6-8% and raises EBIT-margin expectations from 25-26% to now 26-27%. COPENHAGEN, Denmark – August 11, 2022. Novozymes delivers 10% organic sales growth and an EBIT-margin of 26% in the first half of the year, with 18% organic sales growth in DKK. Good mome

  • Globe Newswire

    Novozymes plan to further increase prices across the portfolio in response to the significant and persistent hike in incoming cost

    Novozymes has experienced unprecedented cost-inflation on raw materials, energy, and logistics. To recover these headwinds, substantial price increases will be implemented. COPENHAGEN, Denmark – 15 July 2022. Novozymes has been able to partially shield its customers from a large part of the global challenges, securing business continuity and high price stability relative to other suppliers. However, Novozymes will further substantially increase prices at a level at least in line with the current

  • Zacks

    AXTA vs. NVZMY: Which Stock Is the Better Value Option?

    AXTA vs. NVZMY: Which Stock Is the Better Value Option?